Inventurus Knowledge Solutions Limited
IKS · General/Diversified · NSE
₹1,521
Current Market Price
Fair Value (DCF)
₹771
Margin of Safety
-49.3%
Updated just now
YieldIQ Score
68/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
58%
ROE
27.2%
Debt/Equity
0.00
WACC
12.8%
Market Cap
₹0.25 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
27.5%
Return on capital employed
EV / EBITDA
26.5×
Enterprise multiple
Debt / EBITDA
0.9×
Leverage vs earnings
Interest Coverage
7.8×
EBIT covers interest
Current Ratio
1.50×
Short-term liquidity
Asset Turnover
0.96×
Revenue per ₹ of assets
Revenue CAGR (3Y)
41.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,521.1
Bear case
₹421.52
MoS -260.9%
Base case
₹771.39
MoS -97.2%
Bull case
₹863.83
MoS -76.1%
Ratio Trends
IKS · last 4 annual periods
ROE
27.2%
ROCE
30.5%
Operating Margin
—
Debt / Equity
0.48×
PE
—
EV / EBITDA
—
Historical Financials
IKS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹764 Cr | ₹1031 Cr | ₹1817 Cr | ₹2664 Cr | +51.7% |
| EBITDA | ₹298 Cr | ₹389 Cr | ₹559 Cr | ₹808 Cr | +39.4% |
| EBIT | — | — | — | — | — |
| PAT | ₹233 Cr | ₹305 Cr | ₹370 Cr | ₹486 Cr | +27.8% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹233 Cr | ₹288 Cr | ₹210 Cr | ₹318 Cr | +10.9% |
| CapEx | ₹-10.9 Cr | ₹-8.6 Cr | ₹-32.7 Cr | ₹-42.4 Cr | — |
| FCF | ₹222 Cr | ₹279 Cr | ₹177 Cr | ₹276 Cr | +7.4% |
| Total Assets | ₹788 Cr | ₹988 Cr | ₹3028 Cr | ₹3052 Cr | +57.1% |
| Total Debt | ₹65.2 Cr | ₹52.3 Cr | ₹1311 Cr | ₹856 Cr | +135.9% |
| Shareholders' Equity | ₹647 Cr | ₹829 Cr | ₹1158 Cr | ₹1790 Cr | +40.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
IKS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| LALPATHLAB Dr. Lal Path Labs Ltd. | -45.2% | 58 | Overvalued | 22.1% | — |
| KIMS KIMS | — | — | Pending | 15.9% | — |
| PFIZER Pfizer Limited | +20.0% | 65 | Undervalued | 18.2% | — |
| WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
| ASTRAZEN ASTRAZEN | — | — | Pending | 15.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for IKS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Inventurus Knowledge Solutions Limited (IKS.NS) trades at 1521.10 vs a model fair value of 771.39, a gap of -49.3%. Piotroski F-score: 7/...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of IKS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for IKS →
Compare
Head-to-head with peers
Compare IKS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse IKSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.